South Korea, DIA Explore Collaboration for Training
Korea National Enterprise for Clinical Trials (KoNECT) and DIA (Drug Information Association) have signed a Memorandum of Understanding to establish a cooperative relationship and explore collaboration in development of training, education and knowledge exchange opportunities.
Korea National Enterprise for Clinical Trials (KoNECT) and the DIA have signed a Memorandum of Understanding to establish a cooperative relationship and explore collaboration in development of training, education and knowledge exchange opportunities. Both organizations have an interest in delivering educational offerings through classroom and on-line training courses along with additional opportunities to further develop and advance innovations in therapeutic product development.
KoNECT was established in April, 2014 as a non-profit foundation by the Korean Ministry of Health and Welfare for the purpose of furthering development of clinical trial infrastructure and capability, with an objective to establish Korea as a global clinical trial hub and preferred partner for drug development in the Asia Pacific region, as the continuum of the 1st KoNECT established in December 2007.
Additional information is in this release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
